earnings
confidence high
sentiment positive
materiality 0.65
GRAIL Q3 revenue $36.2M (+26% YoY); U.S. Galleri revenue $32.6M (+28%)
GRAIL, Inc.
2025-Q3 EPS reported
-$8.73
revenue$103,575,000
- Net loss $89.0M, improving 29% YoY; adjusted EBITDA $(71.7)M.
- Galleri tests sold >45,000, up 39% YoY; PMA submission to FDA expected Q1 2026.
- Cash $547.1M at Sep 30; pro forma >$850M after private placement.
- Non-GAAP adjusted gross profit $20.0M (+69% YoY); gross loss $13.7M.